Laferobion suppositories 500000 IU 1g. №10

Description

Laferobion Storage
active substance: interferon alfa-2b

1 suppository contains: recombinant human interferon alfa-2b – 150,000 IU or 500,000 IU;

Excipients: refined sunflower oil, tocopherol acetate, sodium ascorbate, ascorbic acid, solid fat.

Laferobion Dosage form
Suppositories.

Main physical and chemical properties: suppositories of spherical shape of yellowish-white color of homogeneous consistency.

Laferobion Pharmacotherapeutic group
Immunostimulants. Interferons. Interferon alfa-2b.

ATX code L03A B05.

Laferobion Pharmacological properties
Pharmacodynamics

Recombinant interferon alfa-2b has a pronounced antiviral, antiproliferative and immunomodulatory effect. The active substance of the drug Laferobion® – recombinant interferon alfa-2b – has an immunomodulatory effect on T- and B-lymphocytes, normalizes the content of immunoglobulin E, has antiviral activity. No antibodies are formed that neutralize the antiviral activity of recombinant interferon alfa-2b, even when used for 2 years, the functioning of the endogenous system is normalized.

Pharmacokinetics

The pharmacokinetic properties of recombinant interferon alfa-2b have been little studied.

Indication
For children: in the complex therapy of acute respiratory viral infections (ARI).

Contraindication
Hypersensitivity to the components of the drug; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with Kaposi’s sarcoma; severe cardiovascular disease; psoriasis; severe liver and / or kidney dysfunction; epilepsy and other CNS diseases (including functional); chronic hepatitis on the background of progressive or decompensated liver cirrhosis; chronic hepatitis in patients receiving or recently receiving immunosuppressive therapy (except for a short course of corticosteroid therapy); autoimmune hepatitis or other autoimmune diseases in the anamnesis. Inhibition of myeloid hematopoiesis.

Interaction with other medicinal products and other forms of interaction
Caution should be exercised when co-administering opioid drugs, analgesics, hypnotics and sedatives (potentially causing myelosuppressive effect).

When used concomitantly with drugs that are metabolized by oxidation (including xanthine derivatives – aminophylline and theophylline), the possibility of Laferobion® on oxidative metabolic processes should be considered. Serum theophylline concentrations should be monitored and the dosage regimen adjusted if necessary.

The use of the drug in combination with chemotherapeutic drugs (cytarabine, doxorubicin, teniposide, cyclophosphamide) increases the risk of life-threatening toxic effects (their severity and duration).

Concomitant use with zidovudine increases the risk of neutropenia.

Features of application
Laferobion® treatment should be performed under the supervision of a physician.

With long-term use of the drug monitor the general analysis of blood, liver, kidney and thyroid function.

All patients are recommended to have a comprehensive peripheral blood test before and regularly during treatment with mandatory qualitative and quantitative blood tests, as well as biochemical blood tests, including electrolytes, calcium, liver enzymes, and creatinine.

Careful monitoring of serum albumin and prothrombin time is recommended in all patients receiving the drug.